| Immunology of COVID-19: current state of the science N Vabret, GJ Britton, C Gruber, S Hegde, J Kim, M Kuksin, R Levantovsky, ... Immunity 52 (6), 910-941, 2020 | 1719 | 2020 |
| Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis G Disanto, C Barro, P Benkert, Y Naegelin, S Schädelin, A Giardiello, ... Annals of neurology 81 (6), 857-870, 2017 | 999 | 2017 |
| Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study L Kappos, A Bar-Or, BAC Cree, RJ Fox, G Giovannoni, R Gold, ... The Lancet 391 (10127), 1263-1273, 2018 | 966 | 2018 |
| Potassium channel KIR4. 1 as an immune target in multiple sclerosis R Srivastava, M Aslam, SR Kalluri, L Schirmer, D Buck, B Tackenberg, ... New England Journal of Medicine 367 (2), 115-123, 2012 | 417 | 2012 |
| Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system A Baraniskin, J Kuhnhenn, U Schlegel, A Chan, M Deckert, R Gold, ... Blood, The Journal of the American Society of Hematology 117 (11), 3140-3146, 2011 | 369 | 2011 |
| Biliary glycoprotein, a potential human cell adhesion molecule, is down-regulated in colorectal carcinomas. M Neumaier, S Paululat, A Chan, P Matthaes, C Wagener Proceedings of the National Academy of Sciences 90 (22), 10744-10748, 1993 | 292 | 1993 |
| Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study SC Steinberg, RJ Faris, CF Chang, A Chan, MA Tankersley Clinical drug investigation 30, 89-100, 2010 | 290 | 2010 |
| Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study P Benkert, S Meier, S Schaedelin, A Manouchehrinia, Ö Yaldizli, ... The Lancet Neurology 21 (3), 246-257, 2022 | 285 | 2022 |
| Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised … G Attard, L Murphy, NW Clarke, W Cross, RJ Jones, CC Parker, ... The lancet 399 (10323), 447-460, 2022 | 241 | 2022 |
| Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder M Ringelstein, I Ayzenberg, J Harmel, AS Lauenstein, E Lensch, ... JAMA neurology 72 (7), 756-763, 2015 | 233 | 2015 |
| Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy I Ayzenberg, I Kleiter, A Schröder, K Hellwig, A Chan, T Yamamura, ... JAMA neurology 70 (3), 394-397, 2013 | 232 | 2013 |
| Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single … MB Moor, F Suter-Riniker, MP Horn, D Aeberli, J Amsler, B Möller, ... The Lancet Rheumatology 3 (11), e789-e797, 2021 | 208 | 2021 |
| Treatment of progressive multifocal leukoencephalopathy associated with natalizumab W Wenning, A Haghikia, J Laubenberger, DB Clifford, PF Behrens, ... New England Journal of Medicine 361 (11), 1075-1080, 2009 | 197 | 2009 |
| Microglial phagocytosis of apoptotic inflammatory T cells leads to down-regulation of microglial immune activation T Magnus, A Chan, O Grauer, KV Toyka, R Gold The Journal of Immunology 167 (9), 5004-5010, 2001 | 179 | 2001 |
| Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis C Elliott, M Lindner, A Arthur, K Brennan, S Jarius, J Hussey, A Chan, ... Brain 135 (6), 1819-1833, 2012 | 178 | 2012 |
| l-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients N Schwab, T Schneider-Hohendorf, V Posevitz, J Breuer, K Göbel, ... Neurology 81 (10), 865-871, 2013 | 170 | 2013 |
| Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort AK Trampe, C Hemmelmann, A Stroet, A Haghikia, K Hellwig, H Wiendl, ... Neurology 78 (22), 1736-1742, 2012 | 155 | 2012 |
| Escalating immunotherapy of multiple sclerosis: new aspects and practical application Multiple Sclerosis Therapy Consensus Group, P Rieckmann, KV Toyka Journal of neurology 251, 1329-1339, 2004 | 154 | 2004 |
| Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation TFM Andlauer, D Buck, G Antony, A Bayas, L Bechmann, A Berthele, ... Science advances 2 (6), e1501678, 2016 | 149 | 2016 |
| The disease burden of multiple sclerosis from the individual and population perspective: which symptoms matter most? L Barin, A Salmen, G Disanto, H Babačić, P Calabrese, A Chan, ... Multiple sclerosis and related disorders 25, 112-121, 2018 | 147 | 2018 |
